Recently released market study: King Pharmaceuticals Inc. PharmaVitae Profile

Dec. 10, 2009 - PRLog -- This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

* Benchmark King's performance against key rivals in the prescription pharmaceutical sector
* Assess the impact of the acquisition of Alpharma on King's forecast performance
* Analyze how the invalidation of King's Altace and Skelaxin patents will affect the company's revenue performance over 200814

Partial Table of Contents:
-- Full ToC is available at http://www.fastmr.com/catalog/product.aspx?productid=43014&dt=t

ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Executive summary
Quarterly news update
Company introduction
Company sales
Company financials
Key products and competitors
Data sourcing
Sales data
Analyst consensus
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2002-14
Financial performance, 2002-14
King Pharmaceuticals: PharmaVitae forecasts at a glance
Strategic insight
Challenging times as key products face generic competition
Alpharma acquisition has significantly improved King's outlook
King-Alpharma combination creates a key player in the pain market
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Table of Contents
Table of figures
Chapter 3 Quarterly news update
Quarterly sales update, Q2 2009
Product developments
Deals and alliances
Product deals
M&A activity
Company announcements
Future product milestones
Chapter 4 Company introduction
Key findings
Background
Key corporate developments
M&A history
Early M&A following success of Altace
Elan deal creates life after Altace
Mylan acquisition failed to materialize
Alpharma acquisition completed in December 2008
Current corporate structure
Pharmaceuticals business unit structure
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2002-14
Product analysis
Product analysis, 2002-08
Growth drivers
Growth resistors
Product analysis, 2008-14
Growth drivers
Growth resistors
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2008-14
Core analysis, 2008-14
Expiry analysis, 2008-14
Launch/core/expiry configuration, 2008-14
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
Operating costs and profit analysis
Operating costs and profit analysis, 2002-08
Operating cost ratio and profit margin analysis, 2002-08
Operating cost ratio and profit margin analysis, 2008-14
Operating costs and profit analysis, 2008-14
Chapter 7 Key products and competitors
Key findings
Overview
Central nervous system
Remoxy
Overview
Sales forecast
Pipeline drug Remoxy set to launch in 2011 following approval delays
Remoxy's anti-abuse properties target an area of high unmet need
Flector
Overview
Sales forecast
Alpharma launches Flector in US in January 2008
Acurox
Overview
Sales forecast
Acurox proves another promising pain management candidate
Acurox also to target abuse-resistant market
Embeda
Overview
Sales forecast
Embeda gained via Alpharma acquisition
Abuse-resistant oxycodone expected to achieve greater market success
Avinza
Overview
Sales forecast
Once-daily pain treatment Avinza was acquired in 2007
Embeda to cannibalize revenues
Generic threat from Actavis puts long-term sales performance in jeopardy
Following Alpharma acquisition, King chooses Avinza and divests Kadian
Immunology and inflammation
EpiPen
Overview
Sales forecast

For more information or to purchase this report, go to http://www.fastmr.com/catalog/product.aspx?productid=43014

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.